C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H2 2017

Publisher Name :
Date: 16-Aug-2017
No. of pages: 59

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H2 2017

Summary

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor. It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor.

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Immunology, Cardiovascular, Central Nervous System, Infectious Disease and Metabolic Disorders which include indications Inflammation, Metastatic Breast Cancer, Asthma, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Pain, Liver Transplant Rejection, Lung Infections, Lung Transplant Rejection, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Post-Operative Pain, Prostate Cancer, Pulmonary Inflammation, Respiratory Syncytial Virus (RSV) Infections, Solid Tumor, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Influenza Virus Infections.

The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2017, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)

- The report reviews C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects

- The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Overview 7
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment 18
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development 23
AstraZeneca Plc 23
ChemoCentryx Inc 24
Dompe Farmaceutici SpA 24
GlaxoSmithKline Plc 25
Novartis AG 26
Syntrix Biosystems Inc 26
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles 27
AZD-5069 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AZD-5069 + durvalumab - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
danirixin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
DF-2755A - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ladarixin - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Monoclonal Antibody to Antagonize CXCR2 for Oncology - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases and Inflammation - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PAC-G31P - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
reparixin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Antagonize CCR1,4,5,6 and CXCR2,7 for Oncology and Autoimmune Disease - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SX-517 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
SX-576 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
SX-682 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Dormant Products 45
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products 47
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Product Development Milestones 48
Featured News & Press Releases 48
Apr 26, 2017: Trial investigates use of asthma drug for patients with heart conditions 48
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells 49
Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer 49
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells 50
Sep 25, 2013: Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation 51
Jul 10, 2013: Dompé announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true 52
Dec 06, 2012: Dompé Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium 53
Oct 23, 2012: Dompé Announces Enrollment Of First Patient In Phase III Trial On Reparixin 55
Oct 24, 2011: Dompé Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress 56
Oct 13, 2011: Dompé's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Number of Products under Investigation by Universities/Institutes, H2 2017 16
Products under Investigation by Universities/Institutes, H2 2017 17
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by AstraZeneca Plc, H2 2017 23
Pipeline by ChemoCentryx Inc, H2 2017 24
Pipeline by Dompe Farmaceutici SpA, H2 2017 24
Pipeline by GlaxoSmithKline Plc, H2 2017 25
Pipeline by Novartis AG, H2 2017 26
Pipeline by Syntrix Biosystems Inc, H2 2017 26
Dormant Products, H2 2017 45
Dormant Products, H2 2017 (Contd..1), H2 2017 46
Discontinued Products, H2 2017 47

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Routes of Administration, H2 2017 19
Number of Products by Stage and Routes of Administration, H2 2017 19
Number of Products by Molecule Types, H2 2017 21
Number of Products by Stage and Molecule Types, H2 2017 21
  • 2017 Top 5 Cytokines Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 22-Sep-2017        Price: US 4960 Onwards        Pages: 165
    "This report will be delivered in 2-3 business days after the order is placed." The Global Cytokines market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Cytokines in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Cytokines Players in each region, with sales, p......
  • 2017-2022 China Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCare Phar......
  • 2017-2022 Global Top Countries Cytokines Market Report
    Published: 22-Sep-2017        Price: US 4960 Onwards        Pages: 165
    "This report will be delivered in 2-3 business days after the order is placed." The Global Cytokines market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Cytokines in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East an......
  • 2017-2022 India Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In India market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCare Phar......
  • 2017-2022 Japan Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCare Phar......
  • 2017-2022 Malaysia Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Malaysia market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCar......
  • 2017-2022 Philippines Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Philippines market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer Hea......
  • 2017-2022 United States Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer......
  • North America Antibody Services Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 21-Sep-2017        Price: US 4480 Onwards        Pages: 124
    Antibody services include competitively priced packages and purification options for antibody production. Service Providers offer support for different types and steps of antibody production—from peptide design, synthesis, and carrier protein conjugation to animal immunization, serum collection, or hybridoma fusion, titer analysis, and final antibody purification. They also immunize with recombinant proteins or protein fragments provided by the customers(or expressed and purified in labs using c......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs